Halozyme Announces Multiple Commercial Supply Agreements for the Manufacture of rHuPH20

SAN DIEGO, April 5 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the execution of multiple commercial supply agreements with its existing manufacturing partners. Halozyme amended an existing commercial supply agreement with Avid Bioservices, Inc., entered into a new commercial supply agreement with Avid and entered into a new commercial supply agreement with Cook Pharmica LLC. These three agreements are expected to cover the commercial production of recombinant human hyaluronidase (rHuPH20) to be used in the manufacture of both current products as well as certain partnered product candidates such as subcutaneous Herceptin® and GAMMAGARD® with rHuPH20. Subcutaneous Herceptin and GAMMAGARD with rHuPH20 are both currently in Phase 3 clinical trials.

(Logo: http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO)

"We are pleased to strengthen our already robust supply chain for rHuPH20 by securing these commercial supply agreements to support existing products as well as exciting partnered product candidates such as subcutaneous Herceptin and GAMMAGARD with rHuPH20," stated Jonathan E. Lim, M.D., Halozyme's president and CEO. 

Specific financial terms of these commercial supply agreements have not been disclosed.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's product portfolio is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics, including Herceptin® and MabThera®, for up to 13 targets, and with Baxter BioScience to apply Enhanze technology to GAMMAGARD Liquid®. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, (i) statements concerning clinical trials performed by our partners, (ii) activities under certain supply agreements, and (iii) activities under our collaborative partnerships) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

SOURCE Halozyme Therapeutics, Inc.